

12.0492% p.a. ZKB Autocallable Reverse Convertible Defensive on worst of Abbott Laboratories/Bristol Myers Squibb Co/Eli Lilly & Co/Merck & Co/Pfizer Inc

27/08/2025 - 27/08/2027 | Swiss Security Code 147 480 437

Summary

This Summary is to be understood as an introduction to the present Final Terms. Any investment decision in relation to the products must be based on the information contained in the Base Prospectus and in these Final Terms in their entirety and not on the Summary. In particular, each investor should consider the risk factors contained in these Final Terms and in the Base Prospectus.

The Issuer can only be held liable for the content of this Summary if the Summary is misleading, incorrect or contradictory when read together with the other parts of the Final Terms and the Base Prospectus.

| Information on the securities | |
|---|---|
| Type of product: | ZKB Autocallable Reverse Convertible on worst of |
| SSPA category: | Reverse Convertible with Autocallable Feature (1220, acc. Swiss Structured Products Association) |
| ISIN: | CH1474804379 |
| Issuer: | Zürcher Kantonalbank Finance (Guernsey) Limited, Guernsey |
| Underlyings: | Abbott Laboratories/Bristol Myers Squibb Co/Eli Lilly & Co/Merck & Co/Pfizer Inc |
| Initial Fixing Date: | 20/08/2025 |
| Payment Date: | 27/08/2025 |
| Final Fixing Date: | 20/08/2027 |
| Redemption Date: | 27/08/2027 |
| Cap Level: | 80.00% of the Initial Fixing Value |
| Call Level: | 100.00% of Initial Fixing Value |
| Mode of settlement: | cash |
| Coupon: | 12.0492% p.a. of Denomination |
| Information on the offer and admission to trading | |
| Place of the offer: | Switzerland |
| Issue amount / Denomination / Trading units: | USD 98,000, without the right to increase / USD 1,000 Denomination per product / USD 1,000 or multiples thereof |
| Issue price: | 100.00% of Denomination (USD 1,000) |
| Information on listing: | The product shall not be listed on an exchange. |

Final Terms

Derivative Category / Designation

Regulatory Notification

Issuer

Keep-Well Agreement

1. Product specific conditions and product description

Yield Enhancement / Reverse Convertible with Autocallable Feature (1220, acc. Swiss Structured Products Association)

This product does not constitute a collective investment scheme within the meaning of the Swiss Federal Act on Collective Investment Schemes (CISA) and it is not subject to authorisation or supervision by FINMA. The issuer risk is borne by investors.

Zürcher Kantonalbank Finance (Guernsey) Limited, Saint Peter Port, Guernsey
Zürcher Kantonalbank Finance (Guernsey) Limited is a wholly owned and fully consolidated subsidiary of Zürcher Kantonalbank. It is not subject to any direct prudential supervision neither in Guernsey nor in Switzerland and does not have a rating.

Zürcher Kantonalbank Finance (Guernsey) Limited is a fully owned subsidiary of Zürcher Kantonalbank. Zürcher Kantonalbank obtains the following three ratings: Standard & Poor's: AAA, Moody's: Aaa, Fitch: AAA. Zürcher Kantonalbank is committed to Zürcher Kantonalbank Finance (Guernsey) Limited with sufficient financial means, allowing to satisfy any claims of its creditors in due time. The full text of the Keep-Well Agreement, which is subject to Swiss law,

can be found in the publicly available Base Prospectus.

**Lead Manager, Paying Agent,
Exercise Agent and Calculation
Agent**

Zürcher Kantonalbank, Zurich

Swiss Security Code / ISIN

147 480 437 / CH1474804379

**Issue amount /
Denomination / Trading units**

USD 98,000, without the right to increase / USD 1,000 Denomination per product / USD 1,000 or multiples thereof

Issue price

100.00% of Denomination (USD 1,000)

Currency

USD

Currency Hedge

No

Mode of settlement

cash

Underlying(s)

| Underlying | Type of Underlying Domicile | ISIN Bloomberg | Reference exchange/ Price source |
|-------------------------|--------------------------------|-------------------------------|-------------------------------------|
| Abbott Laboratories | common share USA | US0028241000 ABT UN Equity | New York Stock Exchange |
| Bristol Myers Squibb Co | common share USA | US1101221083 BMY UN Equity | New York Stock Exchange |
| Eli Lilly & Co | common share USA | US5324571083 LLY UN Equity | New York Stock Exchange |
| Merck & Co | common share USA | US58933Y1055 MRK UN Equity | New York Stock Exchange |
| Pfizer Inc | common share USA | US7170811035 PFE UN Equity | New York Stock Exchange |

Information on Levels

| Underlying | Initial Fixing Value | Cap Level | Call Level | Ratio |
|-------------------------|----------------------|---|--|-------|
| Abbott Laboratories | USD 131.6073 | USD 105.2858 (80.00% of the Initial Fixing Value) | USD 131.6073 (100.00% of the Initial Fixing Value) | n/a |
| Bristol Myers Squibb Co | USD 48.4103 | USD 38.7282 (80.00% of the Initial Fixing Value) | USD 48.4103 (100.00% of the Initial Fixing Value) | n/a |
| Eli Lilly & Co | USD 705.5976 | USD 564.4781 (80.00% of the Initial Fixing Value) | USD 705.5976 (100.00% of the Initial Fixing Value) | n/a |
| Merck & Co | USD 85.1432 | USD 68.1146 (80.00% of the Initial Fixing Value) | USD 85.1432 (100.00% of the Initial Fixing Value) | n/a |
| Pfizer Inc | USD 25.3533 | USD 20.2826 (80.00% of the Initial Fixing Value) | USD 25.3533 (100.00% of the Initial Fixing Value) | n/a |

* Local taxes, transactions fees and foreign commissions are, if applicable, included in the Initial Fixing Value of each component and are thus borne by the holders of the structured product. This applies particularly, though not exclusively, when exercising rights associated with the structured product and/or a Rebalancing.

Coupon

12.0492% p.a. per Denomination USD 1,000

Interest part: 3.5281% p.a.; Premium part: 8.5211% p.a.

The Coupons are paid out on the respective Coupon Date regardless of the performance of the Underlyings.

**Coupon Date(s)/
Coupon Payment(s)**

| | Coupon Date _t * | Coupon Payment _t |
|--------|----------------------------|-----------------------------|
| t = 1 | 29/09/2025 | 1.0041% |
| t = 2 | 27/10/2025 | 1.0041% |
| t = 3 | 28/11/2025 | 1.0041% |
| t = 4 | 29/12/2025 | 1.0041% |
| t = 5 | 27/01/2026 | 1.0041% |
| t = 6 | 27/02/2026 | 1.0041% |
| t = 7 | 27/03/2026 | 1.0041% |
| t = 8 | 27/04/2026 | 1.0041% |
| t = 9 | 27/05/2026 | 1.0041% |
| t = 10 | 29/06/2026 | 1.0041% |
| t = 11 | 27/07/2026 | 1.0041% |
| t = 12 | 27/08/2026 | 1.0041% |

| | | |
|--------|------------|----------|
| t = 13 | 28/09/2026 | 1.0041 % |
| t = 14 | 27/10/2026 | 1.0041 % |
| t = 15 | 27/11/2026 | 1.0041 % |
| t = 16 | 28/12/2026 | 1.0041 % |
| t = 17 | 27/01/2027 | 1.0041 % |
| t = 18 | 01/03/2027 | 1.0041 % |
| t = 19 | 29/03/2027 | 1.0041 % |
| t = 20 | 27/04/2027 | 1.0041 % |
| t = 21 | 27/05/2027 | 1.0041 % |
| t = 22 | 28/06/2027 | 1.0041 % |
| t = 23 | 27/07/2027 | 1.0041 % |
| t = 24 | 27/08/2027 | 1.0041 % |

* modified following business day convention

Coupon Calculation Method

30/360

**Initial Fixing Date/
Initial Fixing Value**

Abbott Laboratories: Theoretically calculated price on 20/08/2025, 15:04:29 CET
 Bristol Myers Squibb Co: Theoretically calculated price on 20/08/2025, 15:04:29 CET
 Eli Lilly & Co: Theoretically calculated price on 20/08/2025, 15:04:29 CET
 Merck & Co: Theoretically calculated price on 20/08/2025, 15:04:29 CET
 Pfizer Inc: Theoretically calculated price on 20/08/2025, 15:04:29 CET

Payment Date

27/08/2025

Last Trading Date

20/08/2027

**Final Fixing Date /
Final Fixing Value**

Abbott Laboratories: Closing price on New York Stock Exchange on 20/08/2027
 Bristol Myers Squibb Co: Closing price on New York Stock Exchange on 20/08/2027
 Eli Lilly & Co: Closing price on New York Stock Exchange on 20/08/2027
 Merck & Co: Closing price on New York Stock Exchange on 20/08/2027
 Pfizer Inc: Closing price on New York Stock Exchange on 20/08/2027

**Observation Dates/
Early Redemption Dates**

| | Observation Date_t* | Early Redemption Date_t* |
|--------|--------------------------------------|---|
| t = 1 | 20/08/2026 | 27/08/2026 |
| t = 2 | 21/09/2026 | 28/09/2026 |
| t = 3 | 20/10/2026 | 27/10/2026 |
| t = 4 | 19/11/2026 | 27/11/2026 |
| t = 5 | 18/12/2026 | 28/12/2026 |
| t = 6 | 20/01/2027 | 27/01/2027 |
| t = 7 | 22/02/2027 | 01/03/2027 |
| t = 8 | 19/03/2027 | 29/03/2027 |
| t = 9 | 20/04/2027 | 27/04/2027 |
| t = 10 | 20/05/2027 | 27/05/2027 |
| t = 11 | 21/06/2027 | 28/06/2027 |
| t = 12 | 20/07/2027 | 27/07/2027 |

* modified following business day convention

If any relevant exchange is closed on an Observation Date, the next following day where all relevant exchanges are open will be used as Observation Date.

Redemption Date

27/08/2027

Redemption Method

Early Redemption

The Early Redemption depends on the value of the Underlyings on the respective Observation Date.

- If the closing price of all Underlyings on the Observation Date is at or above the Call Level, the product will be redeemed early at Denomination.
- If the closing price of at least one Underlying on the Observation Date is below the Call Level, the product continues.

If no Early Redemption event has occurred, the following redemption scenarios are possible.

Redemption at maturity

If the Final Fixing Value of all Underlyings is at or above the Cap/Cap Level, the product will be redeemed in cash at Denomination.

If the Final Fixing Value of at least one Underlying is below its Cap/Cap Level, the investor receives a cash redemption in the amount of the Denomination multiplied by the Final Fixing Value and divided by the Cap Level of the worst performing Underlying (between Initial Fixing Date and Final Fixing Date).

Listing

The product shall not be listed on an exchange.

Secondary Market

Under normal market conditions, Zürcher Kantonalbank intends to provide bid prices for this

Zürcher Kantonalbank

product on a regular basis. There is no obligation to provide corresponding liquidity. The non-binding indicative quotes can be found at www.zkb.ch/finanzinformationen.

SIX Financial Information: .zkb
Bloomberg: ZKBY <go>
Sales: +41 (0)44 293 66 65

Refinitiv: ZKBSTRUCT
Internet: www.zkb.ch/finanzinformationen

| | |
|---|--|
| Quotation Type | During the lifetime, this product is traded flat accrued interest, i.e. accrued interest is included in the trading price ('dirty price'). |
| Clearing Agent | SIX SIS AG/Euroclear/Clearstream |
| Distribution Fees | Distribution fees in the form of a discount on the Issue price, reimbursement of a part of the Issue price or other one-off and/or periodic charges may have been paid to one or several distribution partners of this product. The Distribution Fees paid out to distribution partners may amount up to 0.63% p.a.. |
| Key elements of the product | A ZKB Autocallable Reverse Convertible Defensive on worst of is an investment instrument that can be redeemed early on defined dates depending on the performance of the Underlyings. The product pays out coupons on defined dates during the term. This product is a combined investment instrument that essentially consists of a fixed income security and the sale of a put option. This allows the investor to benefit from the current volatility of the Underlyings. An above-average return is achieved when prices fall slightly, stagnate or rise slightly. If the Final Fixing Value of all Underlyings is at or above the Cap Level, the investor receives a cash redemption in the amount of the Denomination. If the Final Fixing Value of at least one Underlying is below the Cap Level, the investor will receive a cash redemption in accordance with section "Redemption Method". |
| Tax aspects Switzerland | The product is considered as transparent and has no predominant one-off interest (Non-IUP). The Coupon of 12.0492% p.a. is divided into a premium payment of 8.5211% p.a. and an interest payment of 3.5281% p.a.. The option premium part qualifies as capital gain and is not subject to Swiss income tax for private investors with Swiss tax domicile. The interest payment is subject to income tax at the time of payment. The Swiss withholding tax is not levied. The Federal securities transfer stamp tax is levied on secondary market transactions. The product may be subject to further withholding taxes or duties, in particular under the rules of FATCA or Sect. 871(m) U.S. Tax Code or foreign financial transaction taxes. All payments from this product are made after deduction of any withholding taxes and levies. The information above is a summary only of the Issuer's understanding of current law and practice in Switzerland relating to the taxation of these products. The relevant tax law and practice may change. The Issuer does not assume any liability in connection with the above information. The tax information only provides a general overview and can not substitute the personal tax advice to the investor. |
| Documentation | <p>This document is a non-binding English translation of the Final Terms (Endgültige Bedingungen) published in German and constituting the Final Terms in accordance with article 45 of the Federal Act on Financial Services (FinSA). The English language translation is provided for convenience only.</p> <p>The binding German version of these Final Terms together with the applicable Base Prospectus of the Issuer for the issuance of structured products approved by SIX Exchange Regulation Ltd (together with any supplements thereto, the "Base Prospectus") constitute the product documentation for the present issue.</p> <p>If this structured product was offered for the first time prior to the date of the respective applicable Base Prospectus, the further legally binding product terms and conditions (the "Relevant Conditions") are derived from the Base Prospectus or issuance program which was in force at the time of the first offer. The information on the Relevant Conditions is incorporated by reference of the respective Base Prospectus or issuance program into the applicable Base Prospectus in force at the time of issuance.</p> <p>Except as otherwise defined in these Final Terms, the terms used in these Final Terms have the meaning given to them in the Base Prospectus or the Relevant Conditions. In case of discrepancies between information or the provisions in these Final Terms and those in the Base Prospectus or the Relevant Conditions, the information and provisions in these Final Terms shall prevail.</p> <p>These Final Terms and the Base Prospectus can be ordered free of charge at Zürcher Kantonalbank, Bahnhofstrasse 9, 8001 Zurich, dept. VRIS or by e-mail at documentation@zkb.ch. They are also available on www.zkb.ch/finanzinformationen.</p> |
| Form of securities | Structured products will be issued in the form of uncertificated securities (Wertrechte) and registered as book-entry securities (Bucheffekten) with SIX SIS AG. Investors have no right to require the issuance of any certificates or any proof of evidence for the products. |
| Further information on the Underlyings | Information on the performance of the Underlying/Underlying components is publicly available on www.bloomberg.com . The latest annual reports can be accessed directly via the companies' website. |

Notifications

All notices relating to this product on part of the Issuer, in particular notices relating to the amendment of the terms and conditions, will be published in a legally valid manner at the internet address www.zkb.ch/finanzinformationen for the relevant product. The Swiss security code search button will lead you directly to the relevant product.

Governing Law/ Jurisdiction

Swiss Law/Zurich

Profit and Loss Expectations at Maturity

2. Profit and Loss Expectations at Maturity

ZKB Autocallable Reverse Convertible Defensive on worst of

| Value | Percent | Redemption | Performance in % |
|-------------------------|---------|-------------|------------------|
| Worst Underlying | | | |
| USD 72.384 | -45% | USD 928.48 | -7.15% |
| USD 92.1251 | -30% | USD 1115.98 | 11.60% |
| USD 111.8662 | -15% | USD 1240.98 | 24.10% |
| USD 131.6073 | 0% | USD 1240.98 | 24.10% |
| USD 151.3484 | 15% | USD 1240.98 | 24.10% |
| USD 171.0895 | 30% | USD 1240.98 | 24.10% |
| USD 190.8306 | 45% | USD 1240.98 | 24.10% |

The redemption scenario above neglects Early redemption.

If the Final Fixing Value of all Underlyings is at or above the Cap Level, the performance of the product is always given by the Coupons paid out during the term. However, if the Final Fixing Value of at least one Underlying is below the Cap Level, the investor receives a cash repayment corresponding to the Denomination divided by the Cap Level and multiplied by the Final Fixing Value of the worst performing Underlying. Therefore, the investor may suffer a partial or total loss. The acquisition price is 80.00% of the Initial Fixing Value (Cap Level), which means that the performance of the product is less negative than the performance of the Underlying. This negative performance is reduced by the guaranteed Coupons paid out during the term.

The table above is valid at maturity only and is by no means meant as a price indication for the present product throughout its lifetime. Additional risk factors may have a significant impact on the value of the product during the term. The price quoted on the secondary market can therefore deviate substantially from the above table. For this table it was assumed, that Abbott Laboratories was the worst performing Underlying. This selection is just a representative example of the possible alternatives. Currency risks between the Underlyings and the Product are not considered in the table.

3. Material Risks for Investors

Issuer Risk

Obligations under these products constitute direct, unconditional and unsecured obligations of the Issuer and rank pari passu with other direct, unconditional and unsecured obligations of the Issuer. The value of the product not only depends on the performance of the Underlying and other developments in the financial markets, but also on the solvency of the Issuer, which may change during the term of this product.

Specific product risks

Structured products are complex financial instruments, which entail considerable risks and, accordingly, are only suitable for investors who have the requisite knowledge and experience and understand thoroughly the risks connected with an investment in these structured products and are capable of bearing the economic risks. The loss potential of an investment in ZKB Autocallable Reverse Convertible Defensive on worst of is limited to the difference between the purchase price and the cash redemption amount as defined in 'Redemption Method'. The Coupon, which is paid out in any case, reduces the loss of the product compared to a direct investment in the worst performing Underlying. The product is denominated in USD. If the investor's reference currency differs from the USD, the investor bears the risk between the USD and his reference currency.

4. Additional Terms

Modifications

If an extraordinary event as described in the Base Prospectus occurs in relation to an Underlying/Component of the Underlying or if any other extraordinary event occurs, which makes it impossible or particularly cumbersome for the Issuer, to fulfill its obligations under the products or to calculate the value of the products, the Issuer shall at its own discretion take all the necessary actions and, if necessary may modify the terms and conditions of these products at its own discretion in such way, that the economic value of the products after occurrence of the extraordinary event corresponds, to the extent possible, to the economic value of the products prior to the occurrence of the extraordinary event.

Change of Obligor

The Issuer is entitled at all times and without the consent of the investors to assign in whole (but not in part) the rights and claims under individual products or all of them to a Swiss or foreign subsidiary, branch or holding company of the Zürcher Kantonalbank (the "New

Issuer") to the extent that (i) the New Issuer assumes all of the obligations arising out of the assigned products which the previous Issuer owed in respect of these products, (ii) the Zürcher Kantonalbank enters into a Keep-Well Agreement with the New Issuer with terms equivalent to the one between the Zürcher Kantonalbank and Zürcher Kantonalbank Finance (Guernsey) Limited, (iii) the New Issuer has received from the supervisory authorities of the country in which it is domiciled all necessary approvals for the issue of products and the assumption of the obligations under the assigned products.

**Market Disruptions
Prudential Supervision**

Compare specific provisions in the Base Prospectus.

As a bank within the meaning of the Swiss Federal Act on Banks and Savings Banks (BankG; SR 952.0) and a securities firm within the meaning of the Swiss Federal Act on Financial Institutions (FinIAG; SR 954.1), Zürcher Kantonalbank is subject to the prudential supervision of FINMA, Laupenstrasse 27, CH-3003 Bern, <https://www.finma.ch>.

**Recording of Telephone
Conversations**

Investors are reminded, that telephone conversations with trading or sales units of the Zürcher Kantonalbank are recorded. Investors, who have telephone conversations with these units consent tacitly to the recording.

Further indications

This document constitutes neither an offer nor a recommendation or invitation to purchase financial instruments and can't replace the individual investor's own judgement. The information contained in this document does not constitute investment advice but is intended solely as a product description. An investment decision should in any case be made on the basis of these Final Terms and the Base Prospectus. Particularly, before entering into a transaction, the investor should, if necessary with the assistance of an advisor, examine the conditions for investment in the product in consideration of his personal situation with regard to legal, regulatory, tax and other consequences. Only an investor who is aware of the risks of the transaction and has the financial capacity to bear any losses should enter into such transactions.

Material Changes

Since the end of the last financial year or the date of the interim financial statements, there have been no material changes in the assets, financial or revenue position of the Issuer and Zürcher Kantonalbank.

**Responsibility for the Final
Terms**

Zürcher Kantonalbank, Zurich, and Zürcher Kantonalbank Finance (Guernsey) Limited, Guernsey, assume responsibility for the content of these Final Terms and hereby declare that, to their knowledge, the information contained in these Final Terms is correct and no material circumstances have been omitted.

Zurich, 20/08/2025